DigiFab® in Patients with Severe Preeclampsia

Status: open

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects with Severe Preeclampsia

Treatment for Preeclampsia

Contact Us Or call 251-415-1598

Description

The purpose of this study is to investigate the safety of Digoxin Immune Fab and to see how well it might work to improve symptoms of preeclampsia and improve conditions of prematurity if your baby is born early. Digoxin Immune Fab is approved by the FDA to treat overdoses of digoxin. In this study, Digoxin Immune Fab is being evaluated as a potential treatment for preeclampsia. Because this use needs to be studied, and FDA has not approved its use in pregnant women with severe preeclampsia, it is considered experimental.

Sponsors

This trial is sponsored by Velo Bio, LLC.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.